Ishita Drugs & Industries Ltd — Board Meeting, 12-08-2025: Board Meeting

Ishita Drugs & Industries' Board has approved its unaudited financial results for the quarter ended June 30, 2025. Following input from the Nomination and Remuneration Committee, the Board approved the re-appointment of Mr. Arvind Vilasrao Sapkal as a Non-executive Independent Director for a second five-year term, pending shareholder approval, ensuring continued experienced leadership. The Board also approved an amendment to the notice for the 32nd Annual General Meeting. Crucially for future growth, the company's Board sanctioned pursuing business opportunities in other fields, provided these activities are within the company's Memorandum of Association, allowing for potential diversification and expansion.